Peripheral Neuropathic Pain Clinical Trial
Official title:
Assessment of the Effectiveness of Ethosuximide in the Treatment of Peripheral Neuropathic Pain.
Currently, it is established that the voltage-gated calcium channels modulate pain perception
due to an influence on the neuronal transmission and excitability. In the past, attention has
focused on the modulation of high voltage activated calcium channel. More recently,
scientific interest has proven to the low voltage activated calcium channel, also called
T-type channels. The data from the literature show significant involvement of these channels
in the physiology of nociception and pathophysiology of acute and chronic pain. Moreover, in
several animal pain models (acute, neuropathic, inflammatory), T-type channels inhibition
alleviates painful behaviours.
Analgesics treatments available in clinic are ineffective in some patients with chronic pain
(neuropathic, inflammatory) and often induce deleterious side effects. Thus, the clinical use
of selective inhibitors of T-type channels could not only help the development of new
therapies for the treatment of neuropathic pain (prevalence = 5-8 %), but also have a
pharmaco-economic impact due to the low selling price of their inhibitor currently available:
Zarontin®.
The purpose of this study is to assess the effectiveness of ethosuximide (Zarontin®) on the
pain symptoms and quality of life in patients with peripheral neuropathic pain compared to a
control group.
This is a multicentre, parallel-group, double-blind, randomised clinical trial comparing ethosuximide and inactive control for the treatment of peripheral neuropathic pain, assessed by numerical rating scale and quality of life questionnaire. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03733886 -
Burst Spinal Cord Stimulation for Neuropathic Pain.
|
N/A | |
| Completed |
NCT04494815 -
A Phase 1b Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04431778 -
Evaluation of the Efficacy and Tolerance of Low Doses of Ethosuximide in the Treatment of Peripheral Neuropathic Pain
|
Phase 2 | |
| Completed |
NCT03191136 -
Clinical Trial to Assess the Effect of Food on the Pharmacokinetics of YHD1119 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT05416931 -
ACD440 Gel in Peripheral Neuropathic Pain
|
Phase 2 | |
| Completed |
NCT06234917 -
Increasing Sensori-Motor Rhythm Activity by EEG-Neurofeedback to Reduce the Impact of Pain on Daily Functioning
|
N/A | |
| Completed |
NCT03009500 -
Randomized Controlled Trial of Efficacy and Safety of Local Anesthetics and Steroids for Chronic Peripheral Post-traumatic Neuropathic Pain
|
Phase 3 | |
| Completed |
NCT01524796 -
NEP-TUNE: Neuropathic Pain - Treatment With Pregabalin Under Real-life Conditions in Denmark
|
||
| Completed |
NCT02985216 -
Clinical Trial of YHD1119 in Patients With Peripheral Neuropathic Pain
|
Phase 3 | |
| Recruiting |
NCT04171453 -
Post-marketing Surveillance (PMS) to Observe the Safety and Effectiveness of Lyrica CR Extended Release Tablets
|
||
| Completed |
NCT01737294 -
Observation of the Use of QUTENZA™ in Standard Clinical Practice
|
N/A | |
| Active, not recruiting |
NCT05890053 -
To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral Neuralgia
|
Phase 3 | |
| Completed |
NCT05219812 -
A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain
|
Phase 2 | |
| Terminated |
NCT01293851 -
Molecular-Genetic Mechanisms Associated With Chemotherapy-Induced Nerve Damage
|
||
| Completed |
NCT02209896 -
BlueWind Reprieve System for the Treatment of PNP
|
N/A | |
| Completed |
NCT01240148 -
Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT05817591 -
Response Profiles to High-concentration Capsaicin Desensitization in Patients With Peripheral Neuropathic Pain With or Without Allodynia: a Regional Multicenter Prospective Cohort
|